Discussion on "Gilteritinib Plus Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: Phase 3 Study Design and Preliminary Results"

Larvol Clinic · 2024-09-27T08:16:26.323Z

Background: Gilteritinib is an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor that has demonstrated efficacy with favorable tolerability in patients with FLT3-mutated (FLT3mut+) relapsed/refractory acute myeloid leukemia (AML), including internal t...

Discussion on "Gilteritinib Plus Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: Phase 3 Study Design and Preliminary Results" | Hashnode

Search Hashnode

Gilteritinib Plus Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: Phase 3 Study Design and Preliminary Results

Responses